Not Signed In -
Absence seizure |
|
|
Clinical Trial: To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients with Partial Seizures
This study is no longer recruiting patients.
|
Purpose
To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.
| Condition | Intervention | Phase |
|---|---|---|
| Seizure Disorder, Partial | Drug: Pregabalin | Phase III |
MedlinePlus related topics: Epilepsy
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients with Partial Seizures.
Further Study Details:
Primary Outcomes: Safety Efficacy
Expected Total Enrollment: 500
Expected Total Enrollment: 500
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Must have met the inclusion criteria for the preceding double-blind study
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion Criteria:
- Cannot have absence seizures.
Location Information
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: 1008-010
Last Updated: September 6, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00141388
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 6, 2005
Record first received: August 30, 2005
ClinicalTrials.gov Identifier: NCT00141388
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
